Several million people are exposed to dioxin and dioxin-like compounds, primarily through food consumption. Skin lesions historically called ''chloracne'' are the most specific sign of abnormal dioxin exposure and classically used as a key marker in humans. We followed for 5 years a man who had been exposed to the most toxic dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), at a single oral dose of 5 million-fold more than the accepted daily exposure in the general population. We adopted a molecular medicine approach, aimed at identifying appropriate therapy. Skin lesions, which progressively covered up to 40% of the body surface, were found to be hamartomas, which developed parallel to a complete and sustained involution of sebaceous glands, with concurrent transcriptomic alterations pointing to the inhibition of lipid metabolism and the involvement of bone morphogenetic proteins signaling. Hamartomas created a new compartment that concentrated TCDD up to 10-fold compared with serum and strongly expressed the TCDD-metabolizing enzyme cytochrome P450 1A1, thus representing a potentially significant source of enzymatic activity, which may add to the xenobiotic metabolism potential of the classical organs such as the liver. This historical case provides a unique set of data on the human tissue response to dioxin for the identification of new markers of exposure in human populations. The herein discovered adaptive cutaneous response to TCDD also points to the potential role of the skin in the metabolism of food xenobiotics.
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Dioxin (2, 3, 7, TCDD) is the most potent of a large number of industrial-era halogenated polyaromatic hydrocarbon pollutants, including other dibenzo-pdioxins, dibenzofurans, and certain polychlorinated biphenyls.
Human populations are exposed to low levels of dioxin and dioxin-like compounds, primarily through food consumption (Connor et al., 2008; Schecter et al., 1999) . The risk characterization of dioxin exposure remains difficult to establish, although it is an issue that broadly affects important public health policy decisions (Gies et al., 2007; Steenland et al., 2001) . Thus, chronic exposure to low/moderate doses of dioxin may be involved not only in the classic dioxin toxicity in some genetically predisposed individuals (IARC Monograph, 1997; Aylward et al., 2005) but also in the newly identified role of these compounds in autoimmunity (Brembilla et al., 2011; Marshall and Kerkvliet, 2010; Ramirez et al., 2010) .
In humans, skin lesions called ''chloracne'' are the most visible and consistent response to dioxin exposure and therefore play the role of a sentinel sign for toxicity (Caputo et al., 1988) . The mechanism by which chloracne appears was not previously known and its diagnostic value is not straightforward, especially in mild and sporadic cases, which could still relate to significant exposure (Passarini et al., 2010) . A robust indicator that would trigger specific ecotoxicology diagnostic processes is lacking; in the current situation, it is likely that many cases have not been recognized .
We have previously reported on the TCDD poisoning in Victor Yushchenko with identification and measurement of TCDD metabolites . The maximum accepted daily dose exposure in human is 4 pg/kg, and this patient received a single dose of 20 lg/kg.
With the approval of the patient to release peer-reviewed scientific information on his case, we now report on a set of data that has never been obtained in humans and helps define the phenotype of the dioxin-induced skin pathology.
Histopathological and immunohistochemical evaluation. Sections were cut from formalin-fixed, paraffin-embedded skin biopsy specimens and stained with hematoxylin and eosin. Cytochrome P450 (CYP) 1A1 immunohistochemical analysis was performed with the use of an immunoperoxidase technique according to standard procedures (Lebeau et al., 2005) .
Dioxin analysis. TCDD was determined in lipid extracts from serum and skin samples using gas chromatography with high-resolution mass spectrometry as previously described .
Imaging and volumetric analysis. Radiologic follow-up included highresolution magnetic resonance (MR) imaging examinations of the face and head at 1.5 T and total body positron emission tomography/computed tomography (PET/CT) exams. The acquired MR and PET/CT data obtained for diagnostic, pretherapeutic, and follow-up purposes formed the basis of our volumetric analysis. The total skin volume and the combined volume of all hamartomatous skin lesions in the examined area were calculated separately using commercially available software according to the manufacturers' instructions (GE Healthcare Advantage Windows). Individual skin lesions on each slice were defined by manual contouring, and appropriate thresholding was used to determine total skin volume. The software was used to generate threedimensional representations of the calculated total skin volume and of the calculated volume of all hamartomatous lesions.
Gene expression analysis. Total RNA extracts from skin samples (face) of the patient and four healthy Caucasian men matched for age, sex, race, and site of sampling were prepared as previously reported (Sorg et al., 2008) . RNA quality was assessed using an Agilent 2100 Bioanalyzer with an RNA 6000 Nano LabChip kit. We generated a hybridization mixture containing 15 lg of biotinylated complementary RNA and hybridized it to GeneChip HG U133 Plus 2.0 according to manufacturer's instructions (Affymetrix). To identify differentially expressed transcripts, comparisons were carried out after normalization with the Affymetrix GCOS 1.2 (MAS5) software. (Fujita et al., 2010) and Gene2Promoter and MatInspector from Genomatix software (www.genomatix.de) (Cartharius et al., 2005) . For most of the tested genes, the same responsive elements were found with both resources.
RESULTS

Dioxin-Induced Skin Lesions Progress over Months while Internal Organs Heal
A few hours after dinner in Kiev on 5 September 2004, a 50year-old male patient suddenly became severely ill. Hospital work-up revealed gastritis, colitis with multiple ulcers, hepatitis, and pancreatitis, all compatible with poisoning by an ''unknown substance'' because testing for thallium, arsenic, antimony, mercury, and lead was negative (Ryan, 2011) . Severe facial edema appeared 2 weeks after the poisoning (W2 a.p.). By W6 a.p., the digestive tract symptoms had improved ( Fig. 1 ). However, severe bilateral lower limb neuropathic pain appeared, and electroneuromyography confirmed that this was caused by small fiber peripheral neuropathy (The organs and systems involved, other than the skin, are just cited here. Each will be fully addressed in future publications when the mechanism has been better analyzed by appropriate ongoing data analysis.). Facial involvement worsened with diffuse nodular lesions on an edematous background, sparing of the periocular zone, but major involvement of the ears and retroauricular folds ( Figs with rapid growth into cysts that developed severe painful inflammation. These lesions were clinically very similar to those of severe nodulocystic acne (Plewig and Kligman, 1993) . By W10 a.p., a few scattered cystic lesions had appeared on the body, but it was not until 9 months (M9) a.p. that lesions became widespread over the entire body, including the limbs, with a peak clinical manifestation at M11 a.p (Fig. 1 ). Palms and soles were spared and have remained so for the subsequent years of follow-up. Only a few lesions occurred in the axillary and inguino genital folds.
Skin Lesions Are Hamartomas
The data are based on 52 skin specimens taken over M43, which showed consistently identical aspects. The key features were ''structure loss'' and ''structure gain,'' with preservation of other normal skin structures, thereby compatible with hamartomas (http://en.wikipedia.org/wiki/ Hamartoma) (Albrecht, 1904) .
The structure loss was the disappearance of the sebaceous glands. This loss occurred to a striking extent: on 252 histological slides studied, not a single sebaceous gland was observed (a very conservative estimate of normal numbers would be from 500 to 4500 sebaceous glands observed on 252 slides) (Montagna, 1963) .
The structure gain was the appearance of cystic lesions with epithelial walls showing epidermal-like differentiation with the expected distribution of epidermal keratins (not shown). These lesions (Figs. 3A-C) were either superficial with an open comedo-like aspect or extending much deeper in the dermis, hence resembling infundibular cysts (Plewig and Kligman, 1993) , but with the following distinct characteristics: (1) mantle-like columnar epithelial downgrowths, showing high proliferative activity (Ki67-positive cells, not shown), putatively giving birth to new cysts, resulting in branching cystic figures with downward growth (Figs. 3A-C) and (2) focal expression of CYP1A1, the major dioxin-metabolizing CYP enzyme, in the epithelial walls of the cystic lesions as shown by immunohistochemistry (Figs. 3A and 3C) .
Gene Expression in the Skin
Gene expression as monitored by whole-genome microarrays analysis was strongly altered in this hamartomatous skin, as compared with age, sex, race, and site of sampling skin specimens taken in healthy subjects (Table 1) .
The majority of differentially expressed genes were repressed: thus, when a cutoff of more than twofold was considered for the analysis of skin samples taken at M5 a.p., 530 genes were found to be differentially expressed, 63% of which were repressed. Table 1 shows a more stringent sorting, with only the genes downregulated more than 10-fold and those upregulated more than threefold in skin samples taken M5 a.p.. Table 1 includes in addition (1) the key genes of the aryl hydrocarbon receptor (AhR) dioxin signaling pathway, whatever their modulation, and (2) another transcriptome performed M11 a.p. in order to evaluate the permanence of the altered gene expression, which was found to be quite consistent (see Table 1 , fold changes M5 and M11).
Among the genes known to be involved in AhR/dioxin pathway, the most induced were CYP1A1, CYP1B1, CYP1A2, and the aryl hydrocarbon receptor repressor (AhRR), whereas the AhR itself, its chaperones heat shock protein 90 and prostaglandin E synthase 3 (p23), as well as aryl hydrocarbon receptor nuclear translocator/HIFb genes were not differentially expressed. Real time PCR analysis for AhR, AhRR, CYP1A1, and CYP1A2, performed on independent samples dissected at the same time, confirmed these results (data not shown). This indicates that a strong and sustained induction of the AhR pathway does occur in the skin lesions and provides, for the first time in humans, information on the relative expression of each player under high dioxin exposure.
The most represented structural/functional family of genes differentially expressed was related to lipid metabolism. In this family, all genes were repressed except phospholipase A2 group IIA, which was induced threefold. The repressed genes included some genes specifically involved in sebum lipid metabolism.
AhR-responsive elements were identified in the promoter regions of FADS2, AWAT1, ELOVL3, ALOX15B, and sterol Oacyltransferase 1 genes.
The differentially expressed genes involved in tissue renewing may relate to hamartomas formation. Among the induced genes, gremlin 2 and high temperature requirement factor A serine peptidase 3, which encode for antagonists of the bone morphogenic protein family (BMP), may be highly relevant to the process of hamartomas formation (Sneddon et al., 2006) . Most of the differentially expressed genes from structural/ functional families shown in Table 1 as ''extracellular matrix'' and ''inflammation'' were induced, which was expected from the clinicopathological but does not suggest a specific pattern.
The solute carrier family genes were all strongly repressed except one. This family encodes proteins involved in the trafficking of many compounds including fatty acids, cholesterol, conjugated steroids, eicosanoids, peptides, and numerous drugs. That so many genes of this family/function were repressed suggests that specific studies are indicated for analyzing the link with dioxin toxicity. This also applies to the differentially expressed genes in the functional family of metabolism.
Dioxin Concentrates in the Skin Lesions: The Emergence of a New Compartment Figure 4 shows the progressive decrease of TCDD levels in the serum, which contrasts with an increase of TCDD levels in the skin lesions that reaches a peak at M11 a.p. At that time, TCDD concentration in skin lesions was 10-fold that of serum. This indicates that the skin lesions do constitute a significant novel compartment, which we calculated to be for the face 482 cm 3 or 68.5% of the total skin volume (704 cm 3 ) (Fig. 5 ). Because at M11 a.p. 40% of the total body skin surface was covered with hamartomatous lesions, it can be estimated that during the peak manifestation of the cutaneous disease, the total volume of the hamartomatous compartment could have reached 6400 cm 3 for the entire body, containing about 35 lg TCDD, i.e., 2% of the initial total body burden.
Synopsis of Therapeutical Measures Derived from Observations
We initially observed that any incisional approach resulted in dystrophic healing, which we found to be a dioxin-induced, very fast skin healing response (Barouti et al., 2009) . With this important limiting feature to incisional skin intervention, we found that mechanical dermabrasion and multiple micro punch extraction/aspiration techniques yielded very quick healing (again due to the mechanism cited above) and were cosmetically still satisfactory. These methods allowed both significant pain relief from inflammation and extraction of large amounts of dioxin-rich hamartomatous lesions. A total of 26 procedures were performed on the whole-body skin surface under general anesthesia, from M4 to M46 a.p.
Compassionate use of tumor necrosis factor a (TNF-a) blockade was considered because non-steroidal anti-inflammatory drugs and systemic steroids were not effective. The patient received three infusions of infliximab but because of intolerance was then switched to adalimumab, which was given for M18 (M16th to M34th a.p.).
FIG. 4. Kinetics of TCDD
showing the concentration of dioxin in the skin lesions: the emergence of a new compartment. Despite a progressive decrease in serum TCDD from months 3 to 15 a.p., there was a concomitant increase of TCDD concentration in skin, while the surface of skin involvement spread. For each parameter, the results are expressed as the percentage of the maximum values reached during this period of observation. The maximum values were as follows: (A) for skin lesions: 40% of total body surface area at M11 a.p. (evaluated prospectively by the palm of the hand method; Agarwal and Sahu, 2010) ; (B) for TCDD in serum: 890 pg/g wet weight (ww) at M3 a.p.; (C) for TCDD in skin lesions: 5000 pg/g ww at M11 a.p. At that time, TCDD concentration in skin lesions was therefore 10-fold that of serum. This indicates that the skin lesions do constitute a significant novel compartment, which could have reached 6400 cm3 for the entire body by M11 a.p., containing about 35 lg TCDD, i.e., 2% of the total initial body burden (see Fig. 5 and discussion). Anterior view. Note that most lesions are located in the ear lobes and lateral cheeks. (C) Thick slab reconstruction of an FDG PET data set obtained from a whole-body PET/CT acquisition showing the distribution and the metabolism of the skin lesions on the back of the patient. Posterior view. Note that some lesions display a high metabolism (major FDG uptake, dark spots), whereas other lesions are metabolically less active (moderate FDG uptake, gray spots). ''Metabolism'' refers to FDG uptake, most probably linked to secondary inflammation rather than to CYP1A1/dioxin metabolism.
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The M10 (M24th to M34th a.p.) during which adalimumab blood concentration was maintained at around 10 lg/ml (i.e., 80 mg every other week) corresponded to a progressive but very significant response on the inflammatory component. Generation of new hamartomatous lesions abruptly declined from month 28, but the extent to which this improvement was driven by TNF-a blockade versus the repeated interventional treatment is currently unclear. Moreover, we are aware that no conclusion may be extrapolated about therapeutic results from a single case.
DISCUSSION
This case being historically the one in whom the highest ever number of skin specimens have been obtained in a prospective context over four years, the data strongly support the previously proposed idea that sebaceous gland atrophy might be a major feature of dioxin toxicity (Panteleyev et al., 1997; Suskind, 1985) . In parallel to the observed atrophy of sebaceous glands, several genes encoding for key sebaceous lipid synthesis enzymes were strongly repressed. Because we identified AhRresponsive elements in the promoters of many of these genes, dioxin-induced transcriptional repression of lipid metabolism may be one mechanism driving the atrophy of sebaceous glands. This would also be consistent with the reported negative effect of AhR signaling in adipogenesis (Shimba et al., 2003) .
No specific characteristics had previously been shown to distinguish dioxin-induced skin lesions from those seen in nodulocystic acne or hidradenitis suppurativa (Plewig and Kligman, 1993) . In this study, two distinct pathological signs were consistently identified in the patient's skin: one was a mantle-like outgrowth and the other a reproducible strong focal expression of CYP1A1 in the cyst cell wall. The ''mantle'' is thought to be an early stage in the formation of the sebaceous gland during the so-called sebaceous gland cycle (de Viragh, 1995) . The ontogeny of the dioxin-induced hamartomas might therefore imply reprogramming of the sebaceous gland cycle, where sebaceous differentiation is replaced by a vigorous hamartomatous growth, driven by the dioxin-redistributed growth factors milieu. Transcriptomics in this case pointed to a very compatible pathway, the bone morphogenetic proteins and its antagonists: bone morphogenetic proteins are members of the transforming growth factor-beta family that has a role in proliferation, apoptosis, and differentiation in various tissues and organs, including skin. BMP signaling has been shown to be necessary for maintaining quiescence of adult epidermal stem cells, and it is likely that BMP signaling acts through other pathways in regulating quiescence and proliferation (Kangsamaksin and Morris, 2011; Sneddon et al., 2006) . This needs to be specifically explored, with appropriate experimental models, for deciphering the mechanisms of such morphogenetic properties of dioxin in skin and potentially in other organs.
The strong expression of CYP1A1 protein in the hamartoma cell wall but not in the adjacent skin epithelia, as detected by immunohistochemistry, matches the strong CYP1A1 gene induction found in tissue. It appears to be a candidate new marker of dioxin-induced skin pathology; thus, the striking picture shown in Figure 3C (1) was seen in all biopsy specimens from the patient, (2) was absent in a panel of skin cysts including hidradenitis suppurativa (not shown), (3) was found in patients of a recent chloracne outbreak in Italy (Passarini et al., 2010) (not shown), and more importantly (4) we could observe a sticking identical picture in archival skin specimens from the only previous human case with a similar high level of dioxin exposure, published by Geusau et al. (1999) (not shown, see acknowledgments).
In addition to its potential diagnostic interest, there are two further implications of the strong focal expression of CYP1A1 in the hamartomas.
First, the CYP1A1 may have role in the skin pathology. CYP1A1 expression has been correlated to TCDD toxicity in various in vitro and animal models (Rifkind, 2006) . In particular, arachidonate, the gene pathway metabolism of which was associated to the most differently expressed in the skin of our patient, is a substrate for CYP1A1 and even more CYP1A2. Therefore, bioactive arachidonate derivatives could be involved in some TCDD effects (Rifkind, 2006) .
Second, skin-expressed CYP1A1 may itself play a direct role in the phase I metabolism of dioxin, which we have recently characterized for the first time in humans ). The amount of CYP1A1 protein available through a multitude of skin hamartomas represents a potentially significant source of enzymatic activity, which may add to the xenobiotic metabolism potential of the classical organs such as the liver.
The skin lesions historically called chloracne therefore represent a functional hamartomatous adaptive process to this poison exposure. We have suggested they would better be called ''metabolizing acquired dioxin-induced skin hamartomas'' . Such an adaptive response points to the potential role of the skin in the metabolism of orally introduced xenobiotics, other than dioxin, as well (Rowe et al., 2008) .
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